Old Web
English
Sign In
Acemap
>
authorDetail
>
Rachael Batteson
Rachael Batteson
Oncology
Internal medicine
Medicine
cost effectiveness
Metastatic Urothelial Carcinoma
4
Papers
11
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States.
2019
Journal of Clinical Oncology
Yichen Zhong
Yizhen Lai
Haojie Li
Rachael Batteson
Yang Meng
Tara L. Frenkl
James Luke Godwin
Guru Sonpavde
Show All
Source
Cite
Save
Citations (0)
Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
2019
Rachael Batteson
R. Hart
Matthew Hemstock
Kyna Gooden
Srividya Kotapati
Stéphane Roze
Dawn Lee
A Amadi
Show All
Source
Cite
Save
Citations (2)
Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.
2019
Journal of Clinical Oncology
Javier Sabater
Lewis Ralph
Rachael Batteson
Grant McCarthy
Jaro Wex
Shanti Ricardo Moreno Vera
Martin Becquart
Nadjat Mounedji
Julien Taieb
Marc Peeters
Alfredo Falcone
Show All
Source
Cite
Save
Citations (0)
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
2018
European Urology Oncology
Karl Patterson
Vimalanand S. Prabhu
Ruifeng Xu
Haojie Li
Yang Meng
Natalie Zarabi
Yichen Zhong
Rachael Batteson
James M. Pellissier
Stephen Michael Keefe
Petros Grivas
Ronald de Wit
Show All
Source
Cite
Save
Citations (9)
1